Marconi Rego Barros Júnior

Marconi Rego Barros Júnior

Auto-generated profile, based on publicly available information

Marconi Rego Barros Júnior

Universidade Federal de Pernambuco

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2017 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
Antonio Carlos de FreitasAntonio Carlos de Freitas
Antonio Carlos de Freitas
TOTalita Helena Araújo de Oliveira
Talita Helena Araújo de Oliveira
MBMarconi Rego Barros
Marconi Rego Barros
Venuti AldoVenuti Aldo
Venuti Aldo
The immune response is a key factor in the fight against HPV infection and related cancers, and thus, HPV is able to promote immune evasion through the expression of oncogenes. In particular, the E5 oncogene is responsible for modulation of several immune mechanisms, including antigen presentation and inflammatory pathways. Moreover, E5 was suggested as a promising therapeutic target, since there is still no effective medical therapy for the treatment of HPV-related pre-neoplasia and cancer. Indeed, several studies have shown good prospective for E5 immunotherapy, suggesting that it could be applied for the treatment of pre-cancerous lesions. Thus, insofar as the majority of cervical, oropharyngeal and anal cancers are caused by high-risk HPV (hrHPV), mainly by HPV16, the aim of this review is to discuss the immune pathways interfered by E5 oncoprotein of hrHPV highlighting the various aspects of the potential immunotherapeutic approaches.

5 July 2018 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MBMarconi Rego Barros
Marconi Rego Barros
CMCristiane Moutinho
Cristiane Moutinho
MBMaria Luiza Carneiro Moura Gonçalves Rego Barros
Maria Luiza Carneiro Moura Gonçalves Rego Barros
RLRita de Cássia Pereira de Lima
Rita de Cássia Pereira de Lima
Antonio Carlos de FreitasAntonio Carlos de Freitas
Antonio Carlos de Freitas
Venuti AldoVenuti Aldo
Venuti Aldo
The immune system is composed of immune as well as non-immune cells. As this system is a well-established component of human papillomavirus- (HPV)-related carcinogenesis, high risk human papillomavirus (hrHPV) prevents its routes and mechanisms in order to cause the persistence of infection. Among these mechanisms are those originated from stromal cells, which include the cancer-associated fibroblasts (CAFs), the myeloid-derived suppressor cells (MDSCs) and the host infected cells themselves, i.e. the keratinocytes. These types of cells play central role since they modulate immune cells activities to create a prosperous milieu for cancer development, and the knowledge how such interactions occur are essential for prognostic assessment and development of preventive and therapeutic approaches. Nevertheless, the precise mechanisms are not completely understood, and this lack of knowledge precluded the development of entirely efficient immunotherapeutic strategies for HPV-associated tumors. As a result, an intense work for attaining how host immune response works, and developing of effective therapies has been applied in the last decade. Based on this, this review aims to discuss the major mechanisms of immune and non-immune cells modulated by hrHPV and the potential and existing immunotherapies involving such mechanisms in HPV-related cancers. It is noticed that the combination of immunotherapies has been demonstrated to be essential for obtaining better results, especially because the possibility of increasing the modulating capacity of the HPV-tumor microenvironment has been shown to be central in strengthening the host immune system.

2 May 2018 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
MBMarconi Rego Barros
Marconi Rego Barros
TOTalita Helena Araújo de Oliveira
Talita Helena Araújo de Oliveira
CMCristiane Moutinho
Cristiane Moutinho
Venuti AldoVenuti Aldo
Venuti Aldo
Antonio Carlos de FreitasAntonio Carlos de Freitas
Antonio Carlos de Freitas
The modulation of the host innate immune system is a well-established carcinogenesis feature of several tumors, including human papillomavirus- (HPV-) related cancers. This virus is able to interrupt the initial events of the immune response, including the expression of Toll-like receptors (TLRs), cytokines, and inflammation. Both TLRs and cytokines play a central role in HPV recognition, cell maturation and differentiation as well as immune signalling. Therefore, the imbalance of this sensitive control of the immune response is a key factor for developing immunotherapies, which strengthen the host immune system to accomplish an efficient defence against HPV and HPV-infected cells. Based on this, the review is aimed at exposing the HPV immune evasion mechanisms involving TLRs and cytokines and at discussing existing and potential immunotherapeutic TLR- and cytokine-related tools.

8 November 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KNKamylla Conceição Gomes Nascimento
Kamylla Conceição Gomes Nascimento
ÉLÉlyda Gonçalves Lima
Élyda Gonçalves Lima
ZNZhilbelly Mota Nunes
Zhilbelly Mota Nunes
MJMarconi Rêgo Barros Júnior
Marconi Rêgo Barros Júnior
Marcus BatistaMarcus Batista
Marcus Batista
Antonio Carlos de FreitasAntonio Carlos de Freitas
Antonio Carlos de Freitas
This study evaluated the presence of Human Papillomavirus (HPV) DNA in the cervix and peripheral blood of women with cervical intraepithelial neoplasia (CIN I, II, and III) and healthy individuals. Overall, 139 paired peripheral blood and cervix samples of healthy women and women with CIN I, II, and III (n = 68) were tested for HPV DNA by using standard procedures. Polymerase chain reaction (PCR) sequencing determined HPV types. Quantification of HPV16 E6 and E2 genes was performed to determine viral load and physical state. HPV DNA was detected in the cervix (21.1% in healthy individuals; 48.8–55.5% in CIN patients), blood (46.4% in healthy individuals; 44.1–77.7% in CIN patients) and paired peripheral blood and cervix samples (24% in healthy individuals; 32.5–44.4% in CIN patients). The most frequent types found in the cervix were HPV16, 18, 31, 33, 58, and 70, while HPV16, 18, 33, 58, and 66 were the most frequent types found in the blood. HPV DNA in the cervix was associated with previous sexually transmitted infections (STIs) (p = 0.023; OR: 2.978; CI:1.34–7.821), HPV DNA in the blood (p = 0.000; OR: 8.283; CI:3.700–18.540), and cervical lesions (CIN I/II or III) (p = 0.007). Binomial logistic regression showed that HPV DNA in the blood (p = 0.000; OR: 9.324; CI:3.612–24.072) and cervical lesions (p = 0.011; OR: 3.622; CI:1.338–9.806) were associated with HPV DNA in the cervix. However, we did not find an association between HPV DNA in the blood and cervical lesions (p = 0.385). Our results showed that only HPV DNA found in the cervix was associated with cervical lesions.

Verified
Journal Article
Open access
PDF file
ASAntônio Humberto P. da Silva-Júnior
Antônio Humberto P. da Silva-Júnior
RSRuany Cristyne de Oliveira Silva
Ruany Cristyne de Oliveira Silva
AGAna Pavla A. Diniz Gurgel
Ana Pavla A. Diniz Gurgel
MBMarconi Rêgo Barros-Júnior
Marconi Rêgo Barros-Júnior
KNKamylla Conceição Gomes Nascimento
Kamylla Conceição Gomes Nascimento
Antonio Carlos de FreitasAntonio Carlos de Freitas
Antonio Carlos de Freitas
The persistence of the human papillomavirus type 16 (HPV16) infection on the cervical epithelium contributes to the progression of cervical cancer. Studies have demonstrated that HPV16 genetic variants may be associated with different risks of developing cervical cancer. However, the E5 oncoprotein of HPV16, which is related to several cellular mechanisms in the initial phases of the infection and thus contributes to carcinogenesis, is still little studied. Here we investigate the HPV16 E5 oncogene variants to assess the effects of different mutations on the biological function of the E5 protein. We detected and analyzed the HPV16 E5 oncogene polymorphisms and their phylogenetic relationships. After that, we proposed a tertiary structure analysis of the protein variants, preferential codon usage, and functional activity of the HPV16 E5 protein. Intra-type variants were grouped in the lineages A and D using in silico analysis. The mutations in E5 were located in the T-cell epitopes region. We therefore analyzed the interference of the HPV16 E5 protein in the NF-kB pathway. Our results showed that the variants HPV16E5_49PE and HPV16E5_85PE did not increase the potential of the pathway activation capacity. This study provides additional knowledge about the mechanisms of dispersion of the HPV16 E5 variants, providing evidence that these variants may be relevant to the modulation of the NF-κB signaling pathway.

1 January 2020 in Semina: Ciências Agrárias
Verified
Journal Article
Open access
PDF file
PDPriscila Rocha Duque
Priscila Rocha Duque
ASAntonio Samuel Alves Silva
Antonio Samuel Alves Silva
MJMarconi Rego Barros Júnior
Marconi Rego Barros Júnior
ASAndreza Maria Tenório Sergio
Andreza Maria Tenório Sergio
CBClara Nilce Barbosa
Clara Nilce Barbosa
Porcine circovirus 2 (PCV2) specific antibodies were evaluated in pigs at 15 to 25 weeks of age by immunoperoxidase monolayer assay. Serum samples (n = 575) were obtained from 16 commercial farms located in six states of northeastern Brazil, including two in Ceara (n = 85), three in Rio Grande do Norte (n = 92), two in Paraiba (n = 49), three in Pernambuco (n = 107), two in Alagoas (n = 39), and four in Bahia (n = 203). Out of the 575 evaluated sera, 470 (81.74%) were reagents with antibody titers ranging from 20 to 5,120. All farms presented reactive animals. There was a statistically significant difference in reactivity proportions between the states of Bahia and Ceara (p < 0.05) and between Bahia and Rio Grande do Norte (p < 0.05). This study provides the first serological investigation for PCV2 in pigs from commercial farms in Northeastern Brazil.